New hope for older brain cancer patients: immunotherapy after chemo shows promise
NCT ID NCT04022980
First seen Jan 10, 2026 · Last updated May 12, 2026 · Updated 24 times
Summary
This early-phase study tested whether the immunotherapy drug nivolumab is safe and effective for older adults (65+) with primary CNS lymphoma after they finish high-dose methotrexate chemotherapy. Fourteen participants were enrolled to check for side effects and see if the treatment helps keep the cancer from returning for at least two years. The goal is to improve disease control without requiring lifelong medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN AND NERVOUS SYSTEM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Brookline, Massachusetts, 02215, United States
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
-
The University of Texas - MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
UNC Hospitals, The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27514, United States
Conditions
Explore the condition pages connected to this study.